[A20-33] Belimumab (systemic lupus erythematosus in children and adolescents) - Addendum to Commission A19-94
Last updated 14.05.2020
Commission awarded on 24.03.2020 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Children aged 5 years and older and adolescents with active, autoantibody-positive SLE with a high degree of disease activity despite standard therapy
Due to new information from the commenting procedure now hint of a non-quantifiable added benefit.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.